These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29112587)

  • 1. Incidence of Infusion Site Reactions in Peripheral Fosaprepitant Infusions.
    Gonçalves SC; Sanches SM; Bueno CT; Villela de Castro DL; Damascena A; Santos GRC
    J Infus Nurs; 2017; 40(6):380-383. PubMed ID: 29112587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
    Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.
    Leal AD; Kadakia KC; Looker S; Hilger C; Sorgatz K; Anderson K; Jacobson A; Grendahl D; Seisler D; Hobday T; Loprinzi CL
    Support Care Cancer; 2014 May; 22(5):1313-7. PubMed ID: 24402411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
    Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
    Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fosaprepitant-associated hypersensitivity reactions at a National Cancer Center.
    Laird CM; Glode AE; Schwarz K; Lam ET; O'Bryant CL
    J Oncol Pharm Pract; 2020 Sep; 26(6):1369-1373. PubMed ID: 31955703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic hypersensitivity to fosaprepitant - A report of two cases.
    Baxley A; Lee Z; Medina P
    J Oncol Pharm Pract; 2018 Jan; 24(1):76-78. PubMed ID: 27872331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
    Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
    Sun S; Schaller J; Placek J; Duersch B
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):509-13. PubMed ID: 23860958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
    Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
    Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
    Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infusion Site Reactions: Classification in the Setting of Fosaprepitant Administration With Chemotherapy.
    Segna AN; Baron RH; Cohen B
    Clin J Oncol Nurs; 2020 Dec; 24(6):E79-E84. PubMed ID: 33216065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
    Uchiyama K; Yamada M; Shiiba Y; Kasazaki S; Suga K; Iwabuchi H; Asoda S; Uehara K
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):585-589. PubMed ID: 28790262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methods of preventing phlebitis induced by infusion of fosaprepitant].
    Kohno E; Kanematsu S; Okazaki S; Ogata M; Kanemitsu M; Yamashita H; Syuntou K; Sekita M; Nishioka R; Yoshida H
    Gan To Kagaku Ryoho; 2015 Mar; 42(3):323-6. PubMed ID: 25812501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
    Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
    J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
    Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
    Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
    Bodge M; Shillingburg A; Paul S; Biondo L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.